Amulet Consulting Ltd

Amulet Consulting Ltd offers experienced commercial consultancy for Biotech Companies. The founder Andrew Kay has extensive board and business experience both in Pharmaceutical Biotech and major Pharmaceutical companies. Chairman NeRRe Therapeutics, Chairman Blueberry Therapeutics, Board Advisor KaNDy Therapeutics, Senior Advisor HealthCap VC, Consultant & Advisor to Boards and Executive teams in Biotech and Healthcare companies. Director of Amulet Consulting specialising in advisory roles with biotech. Previously CEO and board member of Algeta (top 25 biotech, oncology, market cap $2.9 Billion) with R&D/manufacturing in Europe and co-promotion in the USA. Previously Chairman of Biotech Wilson Therapeutics exited successfully in 2018 for $855million. Ten years main board experience in Algeta, Renovo, and Novartis Healthcare Committee. Board committee experience includes Audit Committee, Compensation Committee, Corporate Governance and Regulatory Risk Committee and board sub groups for R&D, Manufacturing, Licensing, clinical development. International career spans CEO, country/ business management, marketing, sales, medical/regulatory, manufacturing. Assignments include roles in the USA, UK, Italy, Switzerland and Scandinavia. Wide range of major licensing deals and product launch experience covering the major therapeutic areas and 8 blockbuster launches. In particular: Oncology, Urology, Cardiovascular, Pulmonary....